SCHEMBL4651223

SCHEMBL4651223

COC(=O)c1ccc(N)c(OC)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.43
ALDH1A1 P00352 5/20 0.42
HSD17B10 Q99714 3/20 0.42
CFTR P13569 1/20 0.42
KDM4E B2RXH2 5/20 0.41
GAA P10253 4/20 0.41
GLA P06280 2/20 0.41
IAPP P10997 1/20 0.41
MAPT P10636 4/20 0.40
PKM P14618 1/20 0.40
HPGD P15428 2/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
NQO2 P16083 3/20 0.39
CYP1A2 P05177 2/20 0.39
RECQL P46063 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31512136 1.00 MAPK1 (0.43) MAPK1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL31326436 0.90 MAPK1 (0.39) MAPK1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL31691038 0.90 MAPK1 (0.39) MAPK1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL4653578 0.87 IAPP (0.56) MAPK1ALDH1A1HSD17B10KDM4EGAA
SCHEMBL4652261 0.87 IAPP (0.56) MAPK1ALDH1A1HSD17B10KDM4EGAA
SCHEMBL15962052 0.84 KDM4E (0.51) MAPK1ALDH1A1KDM4EALOX15TSHR
SCHEMBL4652413 0.83 BCL2 (0.44) MAPK1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL15880418 0.83 MAPK8 (0.44) ALDH1A1HSD17B10KDM4EGAAMAPT
SCHEMBL5554420 0.81 MAPK1 (0.46) MAPK1ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL7226331 0.80 KDM4E (0.47) MAPK1ALDH1A1KDM4EGAAIAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286961-A1 SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2023-09-14 US disclosed
WO-2022222871-A1 HETEROCYCLIC COMPOUNDS AS KRAS G12C INHIBITORS BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) 2022-10-27 WO disclosed
EP-1408986-B1 PROTEOMIMETIC COMPOUNDS AND METHODS UNIV YALE (US) 2008-09-24 EP disclosed
US-7312246-B2 Proteomimetic compounds and methods YALE UNIVERSITY (US) 2007-12-25 US disclosed
EP-1408986-A4 PROTEOMIMETIC COMPOUNDS AND METHODS UNIV YALE (US) 2006-01-11 EP disclosed
US-20050215563-A1 Proteomimetic compounds and methods YALE UNIVERSITY 2005-09-29 US disclosed
US-6858600-B2 Proteomimetic compounds and methods YALE UNIVERSITY (US) 2005-02-22 US disclosed
EP-1408986-A2 PROTEOMIMETIC COMPOUNDS AND METHODS YALE UNIVERSITY (US) 2004-04-21 EP disclosed
US-20030008882-A1 Proteomimetic compounds and methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-01-09 US disclosed
WO-2002089738-A2 PROTEOMIMETIC COMPOUNDS AND METHODS YALE UNIVERSITY (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286961-A1 SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS TRPV1, TRPA1, SCN2B MAPK1 3864/4885ALDH1A1 1562/4885HSD17B10 1846/4885
US-20030008882-A1 Proteomimetic compounds and methods PACSIN2, HSP90B1, PHLPP2 MAPK1 3237/4885ALDH1A1 4826/4885HSD17B10 3515/4885
US-20050215563-A1 Proteomimetic compounds and methods PACSIN2, HSP90B1, PHLPP2 MAPK1 3237/4885ALDH1A1 4826/4885HSD17B10 3515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.